Pharmacologic hyperstabilisation of the HIV-1 capsid lattice induces capsid failure.
- Published in:
- eLife, 2024, p. 1, doi. 10.7554/eLife.83605
- By:
- Publication type:
- Article
Works matching DE "GILEAD Sciences Inc."
Results: 116
1
2
There is a balm in Gilead: Idenix's patent infringed but invalid.
- Published in:
- Journal of Intellectual Property Law & Practice, 2015, v. 10, n. 6, p. 392, doi. 10.1093/jiplp/jpv044
- By:
- Publication type:
- Article
3
4-in-1 solution.
- Published in:
- Nature Reviews Microbiology, 2012, v. 10, n. 8, p. 522, doi. 10.1038/nrmicro2842
- By:
- Publication type:
- Article
4
The Balm of Gilead: Is the Provision of Treatment to those Who Seroconvert in HIV Prevention Trials a Matter of Moral Obligation or Moral Negotiation?
- Published in:
- Journal of Law, Medicine & Ethics, 2006, v. 34, n. 4, p. 793, doi. 10.1111/j.1748-720X.2006.00099.x
- By:
- Publication type:
- Article
5
Binding of Dumbbell Oligonucleotides to MoMuLV Reverse Transcriptase: Inhibitory Properties of RNase H Activity.
- Published in:
- E-Journal of Chemistry, 2010, v. 7, n. 3, p. 701, doi. 10.1155/2010/616512
- By:
- Publication type:
- Article
6
BTW.
- Published in:
- Gay & Lesbian Review Worldwide, 2023, v. 30, n. 5, p. 8
- Publication type:
- Article
7
Wide Use of PrEP Raises Hopes—and Questions.
- Published in:
- Gay & Lesbian Review Worldwide, 2017, v. 24, n. 2, p. 5
- By:
- Publication type:
- Article
8
NEW Products.
- Published in:
- 2008
- Publication type:
- Product Review
9
NEW PRODUCTS.
- Published in:
- 2006
- Publication type:
- Product Review
10
Approved indication: hepatitis C.
- Published in:
- 2014
- Publication type:
- Product Review
11
Targeted drugs to tackle hepatitis C.
- Published in:
- Nature, 2013, v. 497, n. 7447, p. 18, doi. 10.1038/497018a
- By:
- Publication type:
- Article
12
Seven days: 18-24 November 2011.
- Published in:
- Nature, 2011, v. 479, n. 7374, p. 450, doi. 10.1038/479450a
- Publication type:
- Article
13
Pfizer to collaborate with Mylan to develop and market Generics in Japan.
- Published in:
- Pulse International, 2012, v. 13, n. 18, p. 8
- Publication type:
- Article
14
Novel HIV-1 treatment Stribild gains regulatory approval.
- Published in:
- Expert Review of Clinical Pharmacology, 2012, v. 5, n. 6, p. 613, doi. 10.1586/ECP.12.67
- By:
- Publication type:
- Article
15
FDA PrEPares to reduce risk of HIV infection with Truvada.
- Published in:
- Expert Review of Clinical Pharmacology, 2012, v. 5, n. 5, p. 499, doi. 10.1586/ECP.12.66
- By:
- Publication type:
- Article
16
Who Urges Action Over Growing Hepatitis Epidemic.
- Published in:
- Clinical Infectious Diseases, 2017, v. 65, n. 2, p. i
- By:
- Publication type:
- Article
17
Switching Course, Gilead Markets HIV Drug for Prevention.
- Published in:
- 2017
- By:
- Publication type:
- Abstract
18
Gilead's Investigational Fixed-Dose Combination of Emtricitabine/Tenofovir Alafenamide Meets Primary 48-Week Objective in Phase 3 Study.
- Published in:
- Clinical Infectious Diseases, 2015, v. 61, n. 10, p. ii, doi. 10.1093/cid/civ853
- Publication type:
- Article
19
Gilead Shares Dip After Warning About Hepatitis C Drug Interaction.
- Published in:
- Clinical Infectious Diseases, 2015, v. 60, n. 10, p. i, doi. 10.1093/cid/civ268
- By:
- Publication type:
- Article
20
1 December News.
- Published in:
- Clinical Infectious Diseases, 2014, v. 59, n. 11, p. i, doi. 10.1093/cid/ciu771
- Publication type:
- Article
21
15 July News.
- Published in:
- Clinical Infectious Diseases, 2014, v. 59, n. 2, p. i, doi. 10.1093/cid/ciu426
- Publication type:
- Article
22
1 July News.
- Published in:
- Clinical Infectious Diseases, 2014, v. 59, n. 1, p. i, doi. 10.1093/cid/ciu317
- Publication type:
- Article
23
1 October News.
- Published in:
- Clinical Infectious Diseases, 2012, v. 55, n. 7, p. i, doi. 10.1093/cid/cis674
- Publication type:
- Article
24
US Food and Drug Administration Approves Gilead's Once-Daily HIV Pill.
- Published in:
- Clinical Infectious Diseases, 2011, v. 53, n. 9, p. 853
- Publication type:
- Article
25
Gilead HIV Drugas Effective as Merck Drug in Trial.
- Published in:
- Clinical Infectious Diseases, 2011, v. 52, n. 12, p. 1, doi. 10.1093/cid/cir314
- Publication type:
- Article
26
Antiviral Briefs.
- Published in:
- AIDS Patient Care & STDs, 2007, v. 21, n. 12, p. 987, doi. 10.1089/apc.2007.9964
- Publication type:
- Article
27
Antiviral Briefs.
- Published in:
- AIDS Patient Care & STDs, 2001, v. 15, n. 7, p. 399, doi. 10.1089/108729101750301951
- Publication type:
- Article
28
COMPASSIONATE USE FOR TENOFOVIR.
- Published in:
- AIDS Patient Care & STDs, 2000, v. 14, n. 2, p. 101
- Publication type:
- Article
29
NDA filed to treat refractory herpes.
- Published in:
- AIDS Patient Care & STDs, 1997, v. 11, n. 2, p. 103
- Publication type:
- Article
30
Pharmacia and Upjohn and Gilead Sciences receive European recommendations for cidofovir.
- Published in:
- AIDS Patient Care & STDs, 1997, v. 11, n. 2, p. 102
- Publication type:
- Article
31
Gilead science announces statistically significant antiviral activity against hepatitis B virus.
- Published in:
- AIDS Patient Care & STDs, 1996, v. 10, n. 6, p. 384
- Publication type:
- Article
32
Hepatitis B drug approved.
- Published in:
- Contemporary OB/GYN, 2002, v. 47, n. 11, p. 124
- Publication type:
- Article
33
Routine HIV Screening in Two Health-Care Settings -- New York City and New Orleans, 2011-2013.
- Published in:
- MMWR: Morbidity & Mortality Weekly Report, 2014, v. 63, n. 25, p. 537
- By:
- Publication type:
- Article
34
Valuation of Corporate Innovation and the Pricing of Risk in the Biopharmaceutical Industry: The Case of Gilead.
- Published in:
- Journal of Applied Corporate Finance, 2018, v. 30, n. 2, p. 92, doi. 10.1111/jacf.12303
- By:
- Publication type:
- Article
35
New Approaches Tackle Rising Pancreatic Cancer Rates.
- Published in:
- JNCI: Journal of the National Cancer Institute, 2014, v. 106, n. 12, p. 6, doi. 10.1093/jnci/dju417
- By:
- Publication type:
- Article
36
THE WEATHERVANE.
- Published in:
- Hawaii Journal of Medicine & Public Health, 2013, v. 72, n. 1, p. 34
- Publication type:
- Article
37
CURRENT CORONAVIRUS (SARS-COV-2) EPIDEMIOLOGICAL, DIAGNOSTIC AND THERAPEUTIC APPROACHES: AN UPDATED REVIEW UNTIL JUNE 2020.
- Published in:
- EXCLI Journal, 2020, v. 19, p. 992, doi. 10.17179/excli2020-2554
- By:
- Publication type:
- Article
38
AIDS Drug Approved to Treat Hepatitis B Infection.
- Published in:
- Clinical Infectious Diseases, 2008, v. 47, n. 8, p. iv
- Publication type:
- Article
39
FDA PANEL UNANIMOUSLY ENDORSES ADEFOVIR DIPIVOXIL FOR HEPATITIS B.
- Published in:
- Clinical Infectious Diseases, 2002, v. 35, n. 7, p. 2
- Publication type:
- Article
40
Cipla plans to sell generic Tamiflu.
- Published in:
- TCE: The Chemical Engineer, 2009, n. 816, p. 12
- Publication type:
- Article
41
Biomedical briefing.
- Published in:
- Nature Medicine, 2014, v. 20, n. 10, p. 1084, doi. 10.1038/nm1014-1084
- Publication type:
- Article
42
Four-in-one HIV pill may be exception among combination drugs.
- Published in:
- Nature Medicine, 2011, v. 17, n. 12, p. 1528, doi. 10.1038/nm1211-1528a
- By:
- Publication type:
- Article
43
News in brief.
- Published in:
- Nature Medicine, 2009, v. 15, n. 10, p. 1102, doi. 10.1038/nm1009-1102
- Publication type:
- Article
44
Pharmaceutical; Trademark; Patents; News.
- Published in:
- Journal of Generic Medicines, 2018, v. 14, n. 3, p. 141, doi. 10.1177/1741134318776412
- By:
- Publication type:
- Article
45
RECOMBINATION.
- Published in:
- Bio-IT World, 2003, v. 2, n. 1, p. 16
- Publication type:
- Article
46
HCV drug tops previous launch records.
- Published in:
- Nature Reviews Drug Discovery, 2014, v. 13, n. 6, p. 405, doi. 10.1038/nrd4356
- Publication type:
- Article
47
Court sides with generics company over Tamiflu patent.
- Published in:
- Nature Reviews Drug Discovery, 2014, v. 13, n. 6, p. 408, doi. 10.1038/nrd4352
- Publication type:
- Article
48
Patent battle lines drawn as sofosbuvir gains approval.
- Published in:
- Nature Reviews Drug Discovery, 2014, v. 13, n. 1, p. 12, doi. 10.1038/nrd4220
- By:
- Publication type:
- Article
49
Market watch: Upcoming market catalysts in Q1 2014.
- Published in:
- Nature Reviews Drug Discovery, 2014, v. 13, n. 1, p. 11, doi. 10.1038/nrd4206
- By:
- Publication type:
- Article
50
First-in-class PI3K inhibitor advances.
- Published in:
- Nature Reviews Drug Discovery, 2013, v. 12, n. 11, p. 817, doi. 10.1038/nrd4174
- Publication type:
- Article